78

78 Publications Verification

Synonyms: EMD 121974

Target:

Integrin TGF-β Receptor Apoptosis PD-1/PD-L1 STAT Akt mTOR

Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC₅₀ values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

78

Cilengitide TFA

78 Publications Verification

Cat. No.: HY-16143

CAS No.: 199807-35-7

Synonyms: EMD 121974 TFA

Target:

Integrin TGF-β Receptor Apoptosis PD-1/PD-L1 STAT Akt mTOR

Cilengitide TFA (EMD 121974 TFA) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC₅₀ values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide TFA inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide TFA inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide TFA can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

37

Pembrolizumab (anti-PD-1)

37 Cited Publications

Cat. No.: HY-P9902A

Synonyms: MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

18

Tomivosertib

18 Cited Publications

Cat. No.: HY-100022

CAS No.: 1849590-01-7

Purity: 99.92%

Synonyms: eFT508

Target:

MNK PD-1/PD-L1

Research Areas:

Cancer

Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC₅₀s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC₅₀=2-16 nM) in tumor cell lines . Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

11

Avelumab

11 Cited Publications

Cat. No.: HY-108730

CAS No.: 1537032-82-8

Synonyms: Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C

Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

11

Avelumab (anti-PD-L1)

11 Cited Publications

Cat. No.: HY-108730A

CAS No.: 1537032-82-8

Purity: 96.02%

Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

6

BMS-1166

6 Cited Publications

Cat. No.: HY-102011

CAS No.: 1818314-88-3

Purity: 99.49%

Target:

PD-1/PD-L1

Research Areas:

Inflammation/Immunology Cancer

BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

6

BMS-1166 hydrochloride

6 Cited Publications

Cat. No.: HY-102011A

CAS No.: 2113650-05-6

Purity: 99.31%

Target:

PD-1/PD-L1

Research Areas:

Inflammation/Immunology Cancer

BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

5

dBET57

5 Cited Publications

Cat. No.: HY-123844

CAS No.: 1883863-52-2

Purity: 99.94%

Target:

PROTACs Epigenetic Reader Domain Apoptosis PD-1/PD-L1 c-Myc

Research Areas:

Neurological Disease Cancer

dBET57 is a potent and selective BRD4_BD1 PROTAC degrader with a DC₅₀ of approximately 500 nM. dBET57 forms a ternary complex with CRL4 ^CRBN and BRD4_BD1, induces the ubiquitination and degradation of BRD4, and indirectly inhibits the transcription of MYCN, c-Myc and PD-L1, ultimately leading to cell cycle arrest and apoptosis. dBET57 can be used in related research on neuroblastoma, non-small cell lung cancer and colorectal cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

PD-1/PD-L1-IN-9

4 Cited Publications

Cat. No.: HY-132192

CAS No.: 2628506-54-5

Purity: 99.59%

Target:

PD-1/PD-L1

Research Areas:

Cancer

PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

PD-1/PD-L1-IN-9 hydrochloride

4 Cited Publications

Cat. No.: HY-132192A

Purity: 99.26%

Target:

PD-1/PD-L1

Research Areas:

Cancer

PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model .

Compare

loading...